Sutent approved in Canada

Pfizer Canada announced May 31, 2006 that its oral multi-targeted agent, SUTENT (sunitinib malate) has been approved by Health Canada for the treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to intolerance or resistance.

Comments are closed.

PHP Code Snippets Powered By : XYZScripts.com